Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
LLY's Q3 results showed a 10% revenue and 19% EPS beat, with operating margin expanding from 40% to 48% YoY, and cash from operations surging to $8.8 billion. Flagship products Mounjaro and Zepbound posted 100%+ YoY revenue growth; late-stage pipeline assets like orforglipron and retatrutide reinforce LLY's GLP-1 leadership. Despite a premium P/E above 45, LLY's PEG ratio of 1.42 signals undervaluation, while strong momentum and innovation offset competitive and psychological resistance risks. jetcityimage/iStock Editorial via Getty Images Demand for GLP-1 products remains strong, which is a major tailwind for the industry's dominator, Eli Lilly ( LLY ). Therefore, it is no wonder that the stock has delivered a total return of 34% after This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of LLY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- ???????2026???Drugs to Watch??????????????????????????11???? [CNET News]CNET News
- Amgen to announce data on obesity drug MariTide at healthcare conference [Yahoo! Finance]Yahoo! Finance
- Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra [Yahoo! Finance]Yahoo! Finance
- What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients [FOX News]FOX News
- This Healthcare Stock Could Be One of the Best Companies to Own in 2026 [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 1/8/26 - Form 4
- 1/6/26 - Form 3
- 1/6/26 - Form 4
- LLY's page on the SEC website